Michael Hoffman Buys 76,344 Shares of Annovis Bio (NYSE:ANVS) Stock

Posted by Brenda Bartman on May 23rd, 2026

Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) Director Michael Hoffman acquired 76,344 shares of Annovis Bio stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $1.87 per share, with a total value of $142,763.28. Following the purchase, the director owned 3,364,883 shares of the company’s stock, valued at $6,292,331.21. This represents a 2.32% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Annovis Bio Stock Performance

Shares of ANVS stock opened at $2.25 on Friday. Annovis Bio, Inc. has a 52-week low of $1.54 and a 52-week high of $5.50. The company has a market capitalization of $77.79 million, a PE ratio of -1.31 and a beta of 1.26. The business’s fifty day moving average is $2.14 and its 200 day moving average is $2.82.

Annovis Bio (NYSE:ANVS – Get Free Report) last posted its earnings results on Friday, May 15th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.23).

Institutional Trading of Annovis Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Annovis Bio by 5.9% during the third quarter. Vanguard Group Inc. now owns 738,003 shares of the company’s stock valued at $1,528,000 after purchasing an additional 41,239 shares during the period. Marshall Wace LLP purchased a new stake in Annovis Bio during the 4th quarter valued at $2,511,000. Renaissance Technologies LLC bought a new stake in Annovis Bio in the 1st quarter worth $775,000. Geode Capital Management LLC increased its holdings in Annovis Bio by 20.6% during the 4th quarter. Geode Capital Management LLC now owns 222,132 shares of the company’s stock valued at $769,000 after purchasing an additional 37,978 shares during the period. Finally, D.A. Davidson & CO. purchased a new position in shares of Annovis Bio during the fourth quarter valued at approximately $556,000. Institutional investors own 15.83% of the company’s stock.

Analysts Set New Price Targets

ANVS has been the subject of a number of research reports. Canaccord Genuity Group reissued a “buy” rating and issued a $17.00 price target on shares of Annovis Bio in a research note on Tuesday, April 14th. Weiss Ratings cut Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $13.50.

Check Out Our Latest Analysis on Annovis Bio

About Annovis Bio

(Get Free Report)

Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.

The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients.

Insider Buying and Selling by Quarter for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.